Novel Antischizophrenia Treatments PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel Antischizophrenia Treatments PDF full book. Access full book title Novel Antischizophrenia Treatments by Mark A. Geyer. Download full books in PDF and EPUB format.
Author: Mark A. Geyer
Publisher: Springer Science & Business Media
ISBN: 3642257577
Category : Medical
Languages : en
Pages : 456
Get Book Here
Book Description
This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume will concentrate on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Author: Mark A. Geyer
Publisher: Springer Science & Business Media
ISBN: 3642257577
Category : Medical
Languages : en
Pages : 456
Get Book Here
Book Description
This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume will concentrate on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Author: Philip D. Harvey
Publisher: Cambridge University Press
ISBN: 1107013208
Category : Medical
Languages : en
Pages : 341
Get Book Here
Book Description
Provides state-of-the-art information about cognition in schizophrenia with a wide ranging focus on measuring and treating cognitive deficits.
Author: Mark A. Geyer
Publisher: Springer Science & Business Media
ISBN: 3642257585
Category : Medical
Languages : en
Pages : 456
Get Book Here
Book Description
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Author: Gerhard Gross
Publisher: Springer Science & Business Media
ISBN: 3642257615
Category : Medical
Languages : en
Pages : 423
Get Book Here
Book Description
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
Author: James M. Ritter
Publisher: Elsevier Health Sciences
ISBN: 0702054976
Category : Medical
Languages : en
Pages : 785
Get Book Here
Book Description
For 25 years, Rang and Dale’s Pharmacology has delivered the core basic and clinical science information required by students and healthcare practitioners worldwide. Authors H. P. Rang, J. M. Ritter, R. J. Flower, and G. Henderson have ensured that the 8th Edition of this easy-to-read, comprehensive text continues the tradition of excellence with new coverage of drugs affecting the skin and new components online at studentconsult.com. Consult this title on your favorite e-reader. Get the essential pharmacology information you need from one authoritative source with an outstanding global reputation for excellence. Progress confidently through all relevant aspects of pharmacology, beginning with a molecular understanding of receptors and drug actions through clinical uses of key groups of drugs. Find important content quickly thanks to a color-coded layout that enables easy navigation and cross-referencing. Master difficult concepts with Key Points boxes, Clinical Uses boxes, and full-color illustrations throughout. Stay up to date with new information in the field, including an all-new chapter on drugs that affect the skin. Take advantage of new and unique features online, including 500+ chapter-specific multiple choice questions for immediate self-assessment. eBook version included! For the first time, you can access the entire book online or offline across all devices with the Student Consult eBook!
Author: André Schmidt
Publisher: Frontiers Media SA
ISBN: 2889193357
Category : Medicine (General)
Languages : en
Pages : 277
Get Book Here
Book Description
Nothing provided
Author: Rudi A.J.O. Dierckx
Publisher: Springer Nature
ISBN: 3030572315
Category : Medical
Languages : en
Pages : 1075
Get Book Here
Book Description
This book provides a comprehensive overview of the use of PET and SPECT in the classic psychiatric disorders such as depression, bipolar disorder, anxiety disorders, and schizophrenia. In addition, it discusses the application of these functional neuroimaging techniques in a variety of other conditions, including sleep disorders, eating disorders, autism, and chronic fatigue syndrome. The new edition has been extensively revised and updated to reflect the latest advances and results in nuclear imaging within the field. Most chapters are written jointly by a clinical psychiatrist and a nuclear medicine expert to ensure a multidisciplinary approach. This state of the art compendium will be of value for all who have an interest in the field of neuroscience, from psychiatrists and radiologists/nuclear medicine specialists to interested general practitioners and cognitive psychologists. Companion volumes on the use of PET and SPECT in neurology and for the imaging of neurobiological systems complete a trilogy.
Author: Prasad, Barre Vijaya
Publisher: IGI Global
ISBN: 1522505202
Category : Medical
Languages : en
Pages : 435
Get Book Here
Book Description
Although the epidemiology of mental illnesses is innately complex, there have been many strides in the diagnosis and treatment of chronic mental illnesses as more research is being conducted in the field. As more information becomes available, mental health professionals are able to develop more effective plans for caring for their patients. Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment examines emergent research on the identification and epidemiology of various mental illnesses. Featuring information on the prevalence of the disease, psychopharmacological advancements, and strategies for the management of chronic mental illnesses, this book is ideally suited for students, psychiatrists, psychologists, neurologists, social workers, rehabilitation therapists, and other health professionals interested in learning more about shifting practices in the mental health sector.
Author: Debarshi Kar Mahapatra
Publisher: CRC Press
ISBN: 1000030504
Category : Business & Economics
Languages : en
Pages : 268
Get Book Here
Book Description
This volume on applied pharmaceutical science and microbiology looks at the latest research on the applications of natural products for drug uses. It focuses on understanding how to apply the principles of novel green chemistry methods in the vital area of pharmaceuticals and covers the important aspects of green microbial technology in the pharmaceutical industry. Chapters include studies on the applications of natural products used in folk and regional medicines, such as for digestive problems, dermatological infections, respiratory diseases, vessel diseases, diarrhea and dysentery, ringworms, boils, fevers (antipyretic), skin and blood diseases, mouth sores, channel discharges, and even cancer. The volume also looks at medical benefit of microbial fermentation for the conservation of nutrients.
Author: Alaine Keebaugh
Publisher: Frontiers Media SA
ISBN: 2889196968
Category : Neurosciences. Biological psychiatry. Neuropsychiatry
Languages : en
Pages : 134
Get Book Here
Book Description
Our brain is endowed with an incredible capacity to be social, to trust, to cooperate, to be altruistic, to feel empathy and love. Nevertheless, the biological underpinnings of such behaviors remain partially hardwired. Seminal research in rodents has provided important insights on the identification of specific genes in modulating social behaviors, in particular, the arginine vasopressin receptor and the oxytocin receptor genes. These genes are involved in regulating a wide range of social behaviors, mother-infant interactions, social recognition, aggression and socio-sexual behavior. Remarkably, we now know that these genes contribute to social behavior in a broad range of species from voles to humans. Indeed, advances in human non-invasive neuroimaging techniques and genetics have enabled scientists to begin to elucidate the neurobiological basis of the complexity of human social behaviors using "pharmacological fMRI" and "imaging genetics". Over the past few years, there has been a strong interest focused on the role of oxytocin in modulating human social behaviors with translational relevance for understanding neuropsychiatric disorders, such as autism, schizophrenia and depression, in which deficits in social perception and social recognition are key phenotypes. The convergence of this interdisciplinary research is beginning to reveal the complex nature of oxytocin’s actions. For instance, the way that oxytocin does influence social functioning is highly related to individual differences in social experiences, but also to the inter-individual variability in the receptor distribution of this molecule in the brain. Remarkably, despite the increasing evidence that oxytocin has a key role in regulating human social behavior, we still lack of knowledge on the core mechanisms of action of this molecule. Understanding its fundamental actions is a crucial need in order to target optimal therapeutic strategies for human social disorders. The originality of this Research Topic stands on its translational focus on bridging the gap between fundamental knowledge acquired from oxytocin research in voles and monkeys and recent clinical investigations in humans. For instance, what are the key animal findings that can import further knowledge on the mechanisms of actions of this molecule in humans? What are the key experiences that can be performed in the animal model in order to answer significant science gaps in the treatment of neuropsychiatric disorders? Hence, within this Research Topic, we will review the current state of the field, identify where the gaps in knowledge are, and propose directions for future research. This issue will begin with a comparative review that examines the role of this peptide in diverse animal models, which highlights the adaptive value of oxytocin’s function across multiple species. Then, a series of reviews will examine the role of oxytocin in voles, primates, and humans with an eye toward revealing commonalities in the underlying brain circuits mediating oxytocin’s effects on social behavior. Next, there will be a translational review highlighting the evidence for oxytocin’s role in clinical applications in psychopathology. Hence, via the continuum of basic to translational research areas, we will try to address the important gaps in our understanding of the neurobiological routes of social cognition and the mechanisms of action of the neuropeptides that guide our behaviors and decisions.
